CA1328401C - Controle du diabete par l'administration d'insuline sous plus d'une forme pharmaceutique - Google Patents

Controle du diabete par l'administration d'insuline sous plus d'une forme pharmaceutique

Info

Publication number
CA1328401C
CA1328401C CA000570144A CA570144A CA1328401C CA 1328401 C CA1328401 C CA 1328401C CA 000570144 A CA000570144 A CA 000570144A CA 570144 A CA570144 A CA 570144A CA 1328401 C CA1328401 C CA 1328401C
Authority
CA
Canada
Prior art keywords
insulin
liver
glucose
hdvi
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000570144A
Other languages
English (en)
Inventor
W. Blair Geho
John R. Lau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SDG Technology Inc
Original Assignee
Technology Unlimited Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technology Unlimited Inc filed Critical Technology Unlimited Inc
Priority to CA000570144A priority Critical patent/CA1328401C/fr
Application granted granted Critical
Publication of CA1328401C publication Critical patent/CA1328401C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA000570144A 1988-06-22 1988-06-22 Controle du diabete par l'administration d'insuline sous plus d'une forme pharmaceutique Expired - Fee Related CA1328401C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA000570144A CA1328401C (fr) 1988-06-22 1988-06-22 Controle du diabete par l'administration d'insuline sous plus d'une forme pharmaceutique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA000570144A CA1328401C (fr) 1988-06-22 1988-06-22 Controle du diabete par l'administration d'insuline sous plus d'une forme pharmaceutique

Publications (1)

Publication Number Publication Date
CA1328401C true CA1328401C (fr) 1994-04-12

Family

ID=4138257

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000570144A Expired - Fee Related CA1328401C (fr) 1988-06-22 1988-06-22 Controle du diabete par l'administration d'insuline sous plus d'une forme pharmaceutique

Country Status (1)

Country Link
CA (1) CA1328401C (fr)

Similar Documents

Publication Publication Date Title
EP0358709B1 (fr) Traitement du diabete par administration de deux formes d'insuline combinees
KR0131087B1 (ko) 인슐린 유사성 성장인자 i을 함유하는 약제학적 제제
Panksepp et al. Insulin, glucose and hypothalamic regulation of feeding
Galloway Treatment of NIDDM with insulin agonists or substitutes
Schiffrin et al. Accommodating planned exercise in type I diabetic patients on intensive treatment
Gedulin et al. Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats
Duckworth et al. Why intraperitoneal delivery of insulin with implantable pumps in NIDDM?
Micossi et al. Free-insulin profiles after intraperitoneal, intramuscular, and subcutaneous insulin administration
Cherrington et al. Arginine infusion in dogs: model for the roles of insulin and glucagon in regulating glucose turnover and free fatty acid levels
Ma et al. Glucocorticoids facilitate mineralocorticoid-induced sodium intake in the rat
US4761287A (en) Diabetes control by serotonin
Rios et al. Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas
US4863901A (en) Use of growth hormone for nitrogen retention under hypocaloric conditions
Dimitriadis et al. Effects of α-glucosidase inhibition on meal glucose tolerance and timing of insulin administration in patients with type I diabetes mellitus
CA1328401C (fr) Controle du diabete par l'administration d'insuline sous plus d'une forme pharmaceutique
LERNER The augmentation effect of secretin on the insulin responses to known stimuli: specificity for glucose
Daugherty Review of insulin therapy
Dimitriadis et al. Effect of twice daily subcutaneous administration of a long-acting somatostatin analog on 24-hour plasma glucose profiles in patients with insulin-dependent diabetes mellitus
Kemmer et al. State of metabolic control determines role of epinephrine-glucagon interaction in glucoregulation in diabetes
AU650050B2 (en) Product and use of it for the treatment of catabolic states comprising authentic IGF-1 and hypocaloric amount of nutritients
IE61841B1 (en) "Diabetic control by combined insulin forms"
Day Amylin analogue as an antidiabetic agent
Meschi et al. Short-term subcutaneous insulin infusion in diabetic children. Comparison with three daily insulin injections
Whitehouse Insulin therapy and its shortcomings–the need for new approaches
Torlone Recombinant human insulin analogues: recommendations for optimal use

Legal Events

Date Code Title Description
MKLA Lapsed